Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability. Stay ahead of ...
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health ...
Reintroduction of the Cyclin A2 gene enables adult human cardiomyocytes to divide, producing functional daughter cells and promoting heart repair. The therapy uses a replication-deficient adenoviral ...
Remibrutinib showed rapid and sustained efficacy in CSU, with significant symptom reduction by week 2, maintained over 52 weeks. The pooled analysis of REMIX-1 and REMIX-2 trials highlighted ...
Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.
Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.
The FDA today approved selumetinib (Koselugo; Alexion, AstraZeneca Rare Disease) for the treatment of adults with ...
For payers, the case for patient engagement in CKD is compelling. It improves outcomes, reduces costs, supports quality metrics and star ratings, and strengthens member satisfaction. But it doesn’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results